Physician profile
Sam Najmabadi
NPI 1639232770
$854.78
in general payments reported to CMS, 2019-2025
3 companies · $329 in 2025
The $329 reported for 2025 was more than what 80% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $12.58 · 2022: $42.25 · 2023: $58.97 · 2024: $282 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $669.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $461.27 | 2024-2025 | Pregnyl, Follistim Aq, Ganirelix Acetate |
| Ferring Pharmaceuticals INC. | $380.93 | 2019-2025 | Menopur |
| Merck Sharp & Dohme LLC | $12.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Najmabadi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.